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ABSTRACT APOBEC3B is a single-stranded DNA cytosine deaminase with beneﬁcial
innate antiviral functions. However, misregulated APOBEC3B can also be detrimental
by inﬂicting APOBEC signature C-to-T and C-to-G mutations in genomic DNA of mul-
tiple cancer types. Polyomavirus and papillomavirus oncoproteins induce APOBEC3B
overexpression, perhaps to their own beneﬁt, but little is known about the cellular
mechanisms hijacked by these viruses to do so. Here we investigate the molecular
mechanism of APOBEC3B upregulation by the polyomavirus large T antigen. First,
we demonstrate that the upregulated APOBEC3B enzyme is strongly nuclear and
partially localized to virus replication centers. Second, truncated T antigen (truncT) is
sufﬁcient for APOBEC3B upregulation, and the RB-interacting motif (LXCXE), but not
the p53-binding domain, is required. Third, genetic knockdown of RB1 alone or in
combination with RBL1 and/or RBL2 is insufﬁcient to suppress truncT-mediated in-
duction of APOBEC3B. Fourth, CDK4/6 inhibition by palbociclib is also insufﬁcient to
suppress truncT-mediated induction of APOBEC3B. Last, global gene expression anal-
yses in a wide range of human cancers show signiﬁcant associations between ex-
pression of APOBEC3B and other genes known to be regulated by the RB/E2F axis.
These experiments combine to implicate the RB/E2F axis in promoting APOBEC3B
transcription, yet they also suggest that the polyomavirus RB-binding motif has at
least one additional function in addition to RB inactivation for triggering APOBEC3B
upregulation in virus-infected cells.
IMPORTANCE The APOBEC3B DNA cytosine deaminase is overexpressed in many
different cancers and correlates with elevated frequencies of C-to-T and C-to-G mu-
tations in 5=-TC motifs, oncogene activation, acquired drug resistance, and poor clin-
ical outcomes. The mechanisms responsible for APOBEC3B overexpression are not
fully understood. Here, we show that the polyomavirus truncated T antigen (truncT)
triggers APOBEC3B overexpression through its RB-interacting motif, LXCXE, which in
turn likely modulates the binding of E2F family transcription factors to promote
APOBEC3B expression. This work strengthens the mechanistic linkage between active
cell cycling, APOBEC3B overexpression, and cancer mutagenesis. Although this muta-
tional mechanism damages cellular genomes, viruses may leverage it to promote
evolution, immune escape, and pathogenesis. The cellular portion of the mechanism
may also be relevant to nonviral cancers, where genetic mechanisms often activate
the RB/E2F axis and APOBEC3B mutagenesis contributes to tumor evolution.
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Genetic diversity is key to virus replication, pathogenesis, and transmission, andparticularly for escape from adaptive immune responses in vertebrate species
(1–3). Each virus has evolved to maintain an optimized level of genetic diversity for its
own unique life cycle through various mechanisms, with some viruses having high
mutation rates and others much lower mutation rates, notably the dsDNA viruses (4, 5).
Recently, it has been concluded that the genome compositions of multiple DNA tumor
viruses, including high-risk human papillomavirus (HPV) types and BK polyomavirus
(BKPyV), have been shaped by long-term interactions with the innate, antiviral APOBEC
deaminases (6–9). It has also been suggested that acutely occurring mutations by these
enzymes in the major capsid gene of polyomaviruses promote antibody escape during
polyomavirus-associated nephropathy and progressive multifocal leukoencephalopa-
thy (10). The overlap between these disease variants and oncogenic enzymes is striking
especially in light of growing evidence linking BKPyV infection and a subset of urothe-
lial carcinomas with high levels of APOBEC-signature mutations (11).
Several APOBEC enzymes, including APOBEC3B (A3B), bind 5=-TC dinucleotide mo-
tifs in single-stranded DNA and catalyze the hydrolytic conversion of cytosine to uracil
(12, 13). Left unrepaired, uracil lesions can serve as the templates for new DNA synthesis
and directly result in C-to-T mutations. Alternatively, if the uracil base is excised by
cellular uracil DNA glycosylase 2 (UNG2), then the resulting abasic site becomes
noninstructional and may trigger cellular DNA polymerases to insert an adenine
opposite the lesion, except for REV1, which tends to incorporate either adenine or
cytosine. Thus, APOBEC-catalyzed DNA deamination of 5=-TC motifs results in both
C-to-T and C-to-G mutations (a signature frequently expanded to include the 3’-
nucleobases A and T and referred to in the context of trinucleotide motifs 5=-TCA and
5=-TCT). An additional hallmark of virus mutagenesis by APOBEC enzymes is a bias
toward occurring on the template of lagging-strand DNA replication (14–16). A likely
mechanistic relationship with single-stranded DNA replication intermediates is sup-
ported by similar correlations in model yeast and Escherichia coli experiments (17, 18).
Human cells have the potential to express up to nine active DNA cytosine deami-
nases (AID, APOBEC1, and A3A/B/C/D/F/G/H) (19–22). Seven of these enzymes prefer
5=-TC motifs in single-stranded DNA, whereas AID uniquely prefers 5=-RC and
APOBEC3G (A3G) prefers 5=-CC. A3B is the most likely APOBEC family member to
contribute to the mutagenesis and evolution of small DNA tumor viruses because it is
speciﬁcally upregulated by viral oncoproteins. For high-risk HPV types, the oncopro-
teins E6 and E7 have been implicated through various pathways (23–26). For polyo-
maviruses, including JC, BK, and Merkel cell (JCPyV, BKPyV, and MCPyV, respectively),
the large T antigen (TAg) is sufﬁcient for A3B upregulation through a yet-to-be
determined mechanism (6). However, the considerable functional overlap of these
proteins, RB inactivation by E7 and TAg and p53 inactivation by E6 and TAg, may
indicate limited pathways for A3B modulation by viruses (27, 28). Here we investigate
the molecular mechanism by which polyomaviruses promote the transcriptional up-
regulation of A3B with results converging on the cellular RB/E2F pathway, which is
often deregulated in cancer.
RESULTS
Visualization of endogenous APOBEC3B protein in polyomavirus-infected cells.
A3B induction by polyomaviruses has been shown at the mRNA level by RT-qPCR and
at the protein level by immunoblotting in primary renal proximal epithelial cells
(RPTECs) (6). To extend these results to other relevant cell types, RT-qPCR and immu-
noﬂuorescent microscopy were used to ask whether polyomavirus infection causes a
general pan-nuclear upregulation of A3B enzyme and/or localization to discrete sub-
nuclear regions such as virus replication centers. Immortalized human kidney
[HuK(i)G10] cells were infected with BKPyV (Dunlop strain) and JCPyV (MAD1 strain) and
subjected to analyses at various days postinfection (dpi). Infected cells have enlarged
nuclei and robust expression of TAg and VP1 at 3 to 5 dpi (Fig. 1A). A3B expression was
more variable but still clearly and signiﬁcantly increased after infection with either virus
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compared to mock-infected controls (Fig. 1A to D). Generally, JCPyV is regarded to have
slower replication dynamics than BKPyV (Dunlop), so initial JCPyV infections were run
out in a time course showing peak A3B expression at 7 dpi (Fig. 1C). Across these
experiments, JCPyV-infected HuK(i)G10 cells showed a greater differential expression of
A3B mRNA and protein compared to mock-treated cells (Fig. 1B to D).
JCPyV-infected cells were also analyzed 7 dpi by high-resolution immunoﬂuorescent
microscopy for expression of A3B and viral proteins and for formation of virus replica-
tion foci. Cells were stained for DAPI, TAg, A3B, and EdU with virus replication centers
appearing as brightly stained puncta positive for both TAg and EdU (representative
images in Fig. 1A and E) (29). In infected cells, A3B is strongly induced with a
pan-nuclear staining pattern that is sometimes coincident with EdU-positive virus
replication foci. Incorporation of EdU into active replication foci is highlighted by strong
positive correlations with TAg stain intensity, as expected, whereas A3B showed weaker
but still signiﬁcantly positive correlations (Fig. 1F and G). These data indicate that A3B
upregulation may be a general property of polyomavirus infection and that A3B may
access at least a subset of virus replication centers.
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FIG 1 Visualization and quantiﬁcation of A3B expression in PyV-infected cells. (A and B) Immunoﬂuorescent images and quantiﬁcation of TAg, VP1, and A3B
in BKPyV-infected HuK(i)G10 cells at 1 and 5 dpi (signiﬁcance determined using Welch’s two-tailed t test; n 2 biological replicates). (C) Time course of A3B
mRNA levels in JCPyV (Mad1 strain) versus mock-infected HuK(i)G10 cells. (D) RT-qPCR quantiﬁcation of A3B transcripts in mock-, BKPyV-, and JCPyV
(Mad1)-infected HuK(i)G10 cells at 6 dpi (signiﬁcance determined by Welch’s two-tailed t test; n 3 technical replicates). (E) High-resolution immunoﬂuorescent
microscopy images of DAPI, A3B, EdU, and TAg in HuK(i)G10 cells infected with JCPyV (Mad1 strain). (F and G) Correlation coefﬁcients and P values for EdU and
A3B levels versus T antigen intensity in 100 cell images from a single experiment similar to that in panel E.
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APOBEC3B upregulation by polyomavirus large T antigen requires the canon-
ical RB-interacting motif LXCXE. Based on the results above and our previous studies
(6), multiple polyomaviruses have the conserved capacity to upregulate A3B expression
in primary and immortalized kidney epithelial cells through the functions of large (L)
TAg. To investigate the LTAg domains responsible for A3B induction, and thus also
implicate associated cellular factors, we tested a naturally occurring splice variant of
BKPyV LTAg, known as truncT, which lacks the DNA-binding and helicase domains
essential for p53 neutralization (30–32) (schematic in Fig. 2A). In parallel, we also
assessed derivatives of LTAg and truncT with a disrupted LXCXE motif, which is required
for inhibiting the tumor suppressor protein RB1 as originally shown for SV40 TAg (33).
RPTECs were transduced with lentiviruses expressing an empty multiple cloning site as
a negative control, BKPyV LTAg as a positive control, BKPyV truncT, and RB-binding site
mutant derivatives; incubated 3 days; and assessed by immunoblotting and ﬂuores-
cence microscopy. Mock-transduced cells express low levels of A3G, and transduction
with empty lentivirus causes a modest increase in this protein and also raises A3B levels
to faintly detectable levels (Fig. 2B). In contrast, both LTAg and truncT induce expres-
sion of A3B and UNG2, a known target of the RB-E2F axis (34), and all induction for both
of these proteins is eliminated by two amino acid substitutions shown to abrogate RB
binding in SV40 TAg (LFCHED to LFCHKK) (33) (Fig. 2B). The LTAg and truncT mutants
invariably migrate faster than the corresponding wild-type proteins during SDS-PAGE,
which is likely due to a charge differential caused by the two amino acid substitutions.
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FIG 2 RB-binding domain is necessary for A3B induction by polyomavirus T antigen. (A) Diagram of BKPyV T antigen isoforms and the LXCXE mutant used
here. (B) Immunoblots for the indicated proteins in RPTECs transduced with a lentiviral vector expressing LTAg, truncT, the indicated mutants, or nothing
(empty). Mock-transduced cells were analyzed in parallel as an additional control. (C) Immunoﬂuorescent microscopy images for truncT, truncT LXCXE mutant,
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Immunoﬂuorescent microscopy images also show truncT-mediated induction of nu-
clear A3B but not by the RB-binding mutant derivative (Fig. 2C).
To date, many aspects of A3B regulation and function have been determined using
normal-like and cancerous mammary epithelial cell lines due to higher capacities for
genetic manipulation over primary cells and greater relevance to cancer (35, 36). To ask
whether TAg induction of A3B also occurs in one of these more tractable systems, the
normal-like mammary epithelial cell line MCF10A was transduced with constructs
expressing BKPyV truncT or the RB-binding mutant and analyzed as described above.
Both immunoblotting and RT-qPCR yielded similar results with truncT but not the
RB-binding mutant causing A3B induction (Fig. 2D and E). Thus, polyomavirus T antigen
appears to possess a conserved, LXCXE-dependent capacity to induce A3B in different
epithelial cell types.
TP53 inactivation is dispensable for APOBEC3B induction. The aforementioned
data comparing LTAg and truncT simultaneously implicate RB1 and demonstrate that
p53 inhibition is not required for A3B induction because truncT completely lacks the
p53 binding domain (Fig. 2). To further ask whether p53 inactivation might inﬂuence
A3B gene expression, we quantiﬁed A3B mRNA levels in two cell lines that have been
used to study A3B regulation, MCF10A and the human estrogen receptor-positive
breast cancer cell line MCF-7L (above and references 35 to 38). Each cell line was
treated with either DMSO or 5 M nutlin, which is a drug that protects p53 from
MDM2-mediated degradation (39). As controls, mRNA levels were quantiﬁed for two
genes activated by p53 (P21, MDM2) (40–43) and one gene repressed by p53 (SLC7A11)
(44, 45). Respectively, the expression of these genes was derepressed or repressed by
nutlin treatment (Fig. 3A and B). In comparison, neither steady-state nor PMA-induced
A3B mRNA levels were changed by nutlin (Fig. 3A and B). Moreover, Cas9-mediated
knockout of TP53 in MCF10A cells also caused no signiﬁcant effect on basal or
PMA-induced A3B expression levels (Fig. 3C and D). These data combine to indicate that
p53 by itself has no signiﬁcant role in the either the PMA-induced pathway or
basal-state transcriptional regulation of A3B, discouraging our original hypothesis (23)
and conﬂicting with published data (38) (see Discussion).
RB-family knockdown is insufﬁcient to induce APOBEC3B expression. RB1 is argu-
ably the most widely studied target of the LXCXE motif of viral proteins such as HPV E7,
adenovirus E1A, and polyomavirus LTAg (27, 31, 32, 46). However, the related pocket
proteins RBL1 (p107) and RBL2 (p130) also have an LXCXE-binding motif, are similarly
targeted and inactivated by LTAg and truncT, and may be involved in A3B regulation
(47–50). The aforementioned viral proteins bind to the hypophosphorylated forms of
RB1, RBL1, and RBL2, which inhibits phosphorylation by cyclin-dependent kinases
(CDKs) and leads to an accelerated cell cycle in part by deregulation of E2F transcrip-
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tional activities. To investigate the roles of RB1, RBL1, and RBL2 in A3B transcriptional
regulation, a series of knockdown experiments was done with siRNAs targeting each of
these factors in RPTECs and MCF10A cells (Fig. 4A to D). RT-qPCR showed that 75%
knockdown was achieved for each targeted gene (upper panels in Fig. 4A and C). As
controls, CCNE2 was upregulated upon RB1 knockdown and UNG2 was moderately
upregulated by RBL2 knockdown (lower panels in Fig. 4A and C). However, no combi-
nation of siRNAs resulted in signiﬁcant upregulation of A3B mRNA levels (lower panels
in Fig. 4A and C). Knockdown of RB1 and RBL1 was validated at the protein level, but
RBL2 could not be clearly discerned with available commercial antibodies (Fig. 4B and
D). In contrast to the RT-qPCR results, protein-level A3B expression did appear to be
elevated upon RBL1 knockdown. These results suggest that depletion of each RB family
member alone or in combination is insufﬁcient to signiﬁcantly upregulate A3B mRNA
levels, at least in these two different normal-like cell types where A3B is induced by TAg
and truncT. However, the observed upregulation at the protein level in RBL1-depleted
cells raises the possibility of an additional layer of regulation that may be posttran-
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scriptional. These results also suggest that truncT may have at least one additional
activity mediated by its LXCXE motif that contributes to A3B upregulation.
Pharmacological inhibition of CKD4/6 does not alter APOBEC3B expression. Pal-
bociclib is a selective inhibitor of CDK4 and CDK6, which are kinases that function
normally to phosphorylate pRB, prevent binding to E2F transcription factors, and
stimulate the expression of many genes involved in cell cycle progression (51–53). To
corroborate the knockdown experiments above, we treated a panel of transformed cell
lines with palbociclib and quantiﬁed mRNA expression levels over time. This panel of
cell lines was constructed based on A3B expression, ranging from low to high (54, 55),
TP53 status, and ability to phosphorylate RB. As a positive control for palbociclib
efﬁcacy, we analyzed expression of CCNE2, which encodes cyclin E2, promotes entry
into S phase, and is a known CDK4/6-RB-regulated gene (56, 57). The majority of cell
lines showed a dose- and time-responsive decrease in CCNE2 mRNA expression
(Fig. 5A). This effect was minimal in HCC1937 and HCC1599 cells, which are known to
display decreased RB phosphorylation (58, 59). In contrast, none of the palbociclib-
treated cell lines showed a reproducible or signiﬁcant change in A3B mRNA expression.
In addition, MCF10A cells were treated with PMA to induce A3B mRNA expression by
the PKC/ncNF-B pathway, and again, palbociclib had little effect (palbociclib added
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treated with 0, 0.5, or 2.5 M palbociclib for 0, 1, or 4 h. (B) RT-qPCR quantiﬁcation of A3B and CCNE2 expression in MCF10A cells pretreated with 0 ng/ml or
25 ng/ml PMA for 3 h prior to treatment with 0, 0.5, or 2.5 M palbociclib for 0, 1, and 3 h. (C) RT-qPCR quantiﬁcation of A3B and CCNE2 expression in MCF10A
cells pretreated with 0, 0.5, or 2.5 M palbociclib for 30 min and then treated with 0 ng/ml or 25 ng/ml PMA for 0, 1, and 3 h.
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post- or pre-PMA addition in Fig. 5B and C). These results combine to indicate that the
kinase activity of CDK4 and CDK6 is dispensable for A3B expression in multiple different
cell lines.
Tumor transcriptome analyses support involvement of the RB pathway in
APOBEC3B regulation. We next used bioinformatics approaches to mine TCGA data
and assess global correlates with A3B mRNA expression in human tumors. First, we
conducted pathway analysis using all genes with signiﬁcant positive correlations
between A3B expression in the TCGA breast tumor cohort. This analysis revealed that
11 of the top 20 signiﬁcantly enriched upstream transcription factors contributing to
this expression pattern are part of the CDK4/6-cyclin D-RB-E2F axis (green-labeled
genes in Fig. 6A). These regulatory factors were either signiﬁcantly activated or inhib-
ited, generally corresponding with known functions, with the net outcome being
accelerated cell cycling (respectively, red and blue bars in Fig. 6A). Upon closer pairwise
examination of effectors in this signal transduction pathway, A3B mRNA expression has
the strongest positive correlations with expression of RBL1, E2F1, E2F2, E2F7, and E2F8
(Fig. 6B).
Last, we expanded this expression correlation analysis to include 22 different tumor
types in TCGA and all 11 APOBEC family members. This global approach further
highlighted strong correlations between A3B and expression of E2F1, E2F2, E2F7, and
E2F8 and indicated that the association between A3B, this signal transduction pathway,
and the cell cycle is evident in many cancer types (Fig. 6C). Heat map intensities also
indicated that A3B is the only APOBEC family member that positively and globally
correlates with activation of the RB-E2F axis. To further reconcile our experimental and
bioinformatics data sets, we used the meta-analysis regulatory data from TargetGen-
eReg (http://www.targetgenereg.org/) to compare the regulation of A3B with known
cell cycle-related genes (60). These results, summarized in Table 1, further indicate that
the A3B mRNA expression proﬁle is consistent with that of a cell cycle-regulated gene
that becomes upregulated during the G2/M phase, which is similar to FOXM1 and
distinct from UNG2, CCNE2, and A3C (the last being an APOBEC3 family member likely
to be regulated by p53).
DISCUSSION
In this study, we investigate the mechanism of A3B upregulation by polyomavirus T
antigen through analyses of separation-of-function mutants, genetic knockdowns,
pharmacologic treatments, and transcriptomic data. We use high-resolution ﬂuores-
cence microscopy to show that polyomavirus infection causes A3B upregulation and
protein accumulation in the nuclear compartment with the potential to access viral
replication foci. Second, we show that the LXCXE motif of LTAg and truncT, which is
well known to inhibit the tumor suppressor RB, is essential for A3B upregulation,
whereas the p53-binding domain is dispensable. Further investigation into this path-
way using genetic and pharmacologic treatments indicate that solely perturbing RB
family members (RB, RBL1, and RBL2) or kinases responsible for their phosphorylation
(CDK4 and CDK6) is insufﬁcient to cause A3B mRNA upregulation. However, bioinfor-
matics analyses of tumor expression data show strong global correlations between A3B
mRNA expression and expression of other genes regulated by the RB-E2F signaling
pathway, including several members of the E2F family of transcription factors.
Additional analysis of cell cycle-regulatory networks using the TargetGeneReg da-
tabase suggest that A3B might be a late cell cycle gene repressed by the RB/E2F family
members associated with the DREAM complex in quiescence and activated by other
transcription factors. Suppression by the DREAM complex is supported by the mild
upregulation of A3B protein observed upon RBL1 knockdown in this study. One
putative activating transcription factor is FOXM1, which was signiﬁcantly enriched as an
upstream regulator of A3B and is known to activate genes in late G2/M (61). Interest-
ingly, in lymphoblastoid B cells, FOXM1 has been reported to frequently cooccupy
NF-B binding sites and form protein complexes with NF-B transcription factors, which
have been implicated in A3B regulation (36, 62). Taken together, these results indicate
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FIG 6 Evidence for A3B regulation by the RB/E2F pathway in tumors. (A) Top 20 hits from IPA enrichment analysis of upstream
transcriptional regulators of A3B in TCGA breast cancer with RB-pathway/cell cycle-related genes highlighted in green. Negative logs
of enrichment P values are shown in the bar graph on the right colored by predicted activation (red) or inhibition (blue) of the speciﬁc
transcription factor. (B) Scatter plots showing the correlation between A3B mRNA levels and transcription factors in the RB pathway
with Spearman’s correlation coefﬁcient and q value reported in the lower left corner of each subpanel. (C) Spearman’s correlation
coefﬁcient values for all APOBEC-family members against RB pathway transcription factors across 22 cancers ordered by hierarchal
clustering. Negative correlations are shown in blue, positive correlations are shown in red, and no data is represented by grey.
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that the RB/E2F pathway, which is commonly modiﬁed in cancer, likely contributes to
A3B overexpression observed in virus infections and in different tumor types, but
additional unknown signals are also likely to be required for full induction (model in
Fig. 7).
Our original studies with HPV and A3B led us to propose a model in which p53
represses A3B transcription and that p53 inactivation by the viral oncoprotein E6 or by
genetic mutation results in derepression of A3B transcription (23). This transcription
repression model is consistent with strong correlations in tumors and cell lines between
A3B overexpression and TP53 inactivation (54). A recent study conﬁrmed these corre-
lations and used pharmacologic and genetic approaches to provide further support for
such a model (38). However, three different results in the cell-based systems presented
here do not support a dominant role for p53 in A3B repression. Speciﬁcally, the p53
binding domain of BKPyV is dispensable for A3B upregulation, nutlin treatment has no
effect on basal or induced A3B expression, and p53 knockout alone fails to induce A3B
expression (Fig. 2 and 3). Moreover, another recent study showed that p53 inactivation
renders cells more permissive for A3B mutagenesis (55). Therefore, we disfavor a
transcriptional role and now favor a “tolerance model” in which p53 inactivation
(genetic, epigenetic, or viral) is required for cells to be able to tolerate the increased
levels of DNA damage caused by A3B overexpression. This model also explains why
somatic TP53 mutations were identiﬁed as a signiﬁcant global correlate with A3B
overexpression in cancer (11).
The RB-E2F signaling axis is one of the most frequently mutated pathways in cancer,
which contributes to several hallmarks of cancer by deregulating the cell cycle (63). RB
TABLE 1 Cell cycle analysis of A3B and other cell cycle-regulated genes
Type of value
Value for gene:
APOBEC3B APOBEC3C CCNE2 FOXM1 UNG2
Chromosome 22 22 8 12 12
p53 expression score 4 14 14 17 14
No. of cell cycle data sets 2 1 5 2 5
G1/S or G2/M G2/M 0 G1/S G2/M G1/S
p53 target No Yes No No No
Cell cycle gene Yes No Yes Yes Yes
DREAM target Yes No No Yes Yes
MMB-FoxM1 target No No No No No
RB-E2F target No No Yes No Yes
p21
CyclinD1
Rb
CDK4/6
Deleted/Suppressed
Amplified/Overexpressed
PyV LTAg
PyV truncT
p107 p130
P PP
p53 PyV LTAg
Palbociclib
ncNFκB
A3B
TEAD
Other regulators
FIG 7 Model for A3B transcriptional regulation. Schematic of the cell cycle-related proteins affected by
T antigen and drug treatments used in this study with implications for A3B transcriptional regulation.
Solid lines represent established processes, and dashed lines represent regulatory interactions/pathways
implicated by our studies.
Starrett et al. ®
January/February 2019 Volume 10 Issue 1 e02690-18 mbio.asm.org 10
 o
n
 April 15, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
inactivation is also a common target for viral genes in order to promote the survival of
infected cells. The integration and continued expression of viral oncogenes in the host
genome are common characteristics of virus-associated tumors. For example, HPV-
positive tumors frequently express the viral E7 oncoprotein, which also has an LXCXE
motif, and this is thought to be critical for tumor development (64, 65). These tumors
also tend to have a high burden of APOBEC-associated mutations on the DNA strand
that serves as the template for lagging-strand replication, which is synthesized during
the S phase of the cell cycle (11, 14, 17). Although some of these effects have been
explained by perturbations to the p53 pathway, other pathways affected by E6 have
also been shown to alter A3B gene expression, such as those regulated by the TEAD and
ZNF384 transcription factors (23, 25, 36, 38). It is therefore not surprising in hindsight
that expression of the antiviral enzyme A3B is also induced upon disruption of the
RB-E2F pathway. This idea is supported by a study showing that high-risk HPV E7 is
capable of upregulating A3B (26). An additional study also found that elevated A3B
expression is signiﬁcantly correlated with proliferative features in breast cancer (66).
Last, the LXCXE motif may be acting through another cellular signaling pathway. For
instance, the LXCXE of various viral proteins triggers activation of the antiviral cGAS-
STING pathway, which could also contribute to A3B transcriptional regulation (67).
All of these results combine to indicate that A3B transcriptional regulation is
complex and governed by multiple pathways and different transcription factors. Per-
haps linkage to the cell cycle evolved to prevent potentially oncogenic mutations of the
host genome during normal cellular DNA replication or, alternatively, to maximize
antiviral responses during particularly susceptible cell cycle stages. Further experiments
using mutant viral oncogenes as molecular probes, such as T antigen, E6, and E7, are
likely to continue to provide valuable insights into the regulation of A3B and lead to a
greater understanding of its roles in tumorigenesis, virus evolution, and antiviral
immunity.
MATERIALS AND METHODS
Cell lines, culture conditions, and lentivirus production. Primary renal proximal tubule epithelial
cells (RPTECs; Lonza) were grown in REGM (Lonza). MCF10A cells were grown in MEGM (Lonza)
containing penicillin (100 U/ml) and streptomycin (100 g/ml). HuK(i)G10 cells were grown in RenaLife
epithelial medium (Lifeline Cell Technologies) with 5% FBS. MCF7 and derivative cell lines were grown
in Richter’s modiﬁcation medium containing 5% fetal bovine serum, penicillin (100 U/ml), streptomycin
(100 g/ml), and 11.25 nM recombinant human insulin. All cell lines were grown at 37°C in a 5% CO2
incubator. Lentiviruses expressing TAg and mutant derivatives were produced in 293T cells and trans-
duced into RPTECs as described previously (23).
Antibodies. Large T and truncT forms of BKPyV T antigen were detected using pAb416 (30). JCPyV
large T antigen was detected using PAB2000 (68). A Harris lab custom rabbit anti-human A3B monoclonal
antibody, 5210.87.13, was used in immunoblotting assays and in high-resolution immunoﬂuorescent
microscopy experiments with JCPyV-infected HuK(i)G10 cells (69). Santa Cruz sc-130688 was used for A3B
quantiﬁcation and lower-resolution microscopy of BKPyV- and JCPyV-infected HuK(i)G10 cells (69). UNG2
was detected using the Abcam antibody ab23926. RB1 was detected using Santa Cruz sc-102, and RBL1
was detected using Cell Signaling 89798, whereas RBL2 could not be detected in immunoblots with
Abcam antibody ab71143. TP53 (p53) was detected using clone DU-1 (Santa Cruz SC-126), p21 using CST
clone 1201 (CST no. 2947), and beta-actin using CST clone 13E5 (CST no. 4970).
RNA isolation, RT-qPCR, and immunoblots. Total RNA was harvested by removal of medium and
resuspension in TRIzol (Thermo Fisher), and puriﬁcation was done per the manufacturer’s protocol.
RT-qPCR was used to quantify A3B and UNG2 transcripts in siRNA experiments as described previously
(11, 23) and these methods were adapted for CCNE2. Protein lysates from virus and siRNA experiments
were harvested at 3 or 7 dpi or postransduction, quantiﬁed, and immunoblotted as described previously
(70). Data were plotted and t tests were calculated using GraphPad Prism 7.
Immunoﬂuorescent microscopy experiments. HuK(i)G10 kidney cells were seeded at 6,000 cells/
well in a 96-well plate. Twenty-four hours later, infection with JCPyV was performed as described, and
then cells were collected 7 dpi. Infected cells were incubated with EdU (Click-iT Plus EdU Alexa Fluor 647
imaging kit; Thermo Fisher Scientiﬁc) for 15 min and incubated with CSK buffer (10 mM HEPES-KOH, pH
7.4; 300 mM sucrose; 100 mM NaCl; 3 mM KCl; 0.5% Triton X-100) (71) for 2 min on ice. Cells were then
ﬁxed in 4% PFA for 10 min followed by permeabilization with 0.5% Triton X-100 for 20 min. For EdU
detection, the Click-iT reagent was added for 30 min in the dark according to the manufacturer’s protocol
and washed three times with PBS. Samples were incubated with BlockAid blocking solution (Thermo
Fisher) for 1 h at room temperature. T antigen, VP1, and A3B staining was performed using the
aforementioned antibodies at 1:1,000, 1:1,000, and 1:100 (1:50 for sc-130688) dilutions in BlockAid,
respectively, overnight at 4°C followed by staining with the secondary antibodies for 1 h at room
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temperature. Images were acquired on the Opera Phenix (PerkinElmer) with the confocal 63 water
objective. Immunoﬂuorescence in RPTE cells was performed as described using the above-mentioned
antibodies and imaged on the Invitrogen EVOS FL Imaging System (72).
siRNA and expression construct transfection. siRNAs targeting RB1 (J-003296-23; Dharmacon),
RBL1 (SI02629921; Qiagen), and RBL2 (sc-29425; Santa Cruz) and ﬂuorescein-conjugated nontargeting
control siRNA (sc-36869; Santa Cruz) were purchased and diluted to a working concentration of 20 M.
A ﬁnal concentration of 20 nM was used for all targets in RPTECs, and 40 nM was used in MCF10A cells.
siRNAs were delivered to cells using Lipofectamine RNAiMax (Thermo Fisher) as described previously (73).
Drug treatment. Cells were treated with 5 M nutlin (Sigma) for 24 h, and after 18 h of treatment,
25 ng/ml phorbol myristate acetate (PMA; Sigma) was added for the ﬁnal 6 h prior to RNA extraction.
MCF10A cells were treated only with PMA or DMSO, and RNA was isolated 6 h after treatment. For the
palbociclib experiments, MCF10A and MCF7 (p53 WT and low A3B expression); HCC1937 and HCC1395
(low A3B expression); T47D, HCC1954, and Hs578T (intermediate A3B expression); and HCC1599,
HCC1143, SUM-225-CWN, and HCC202 (high A3B expression) cells were cultured in 6-well plates (Costar
3516; Corning Incorporated) until 70% conﬂuence. Palbociclib (S1116; Selleckchem) was stored as a 5 mM
solution in H2O and added to cells at concentrations of 0 M (H2O control), 0.5 M, and 2.5 M. No
palbociclib was added to cells of the 0-h time point, which instead was transferred to ice prior to RNA
isolation. RNA was also isolated at 0, 1, and 4 h post-palbociclib administration (total RNA puriﬁcation kit
37500; Norgen), and cDNA was synthesized with 500 ng RNA (iScript 170-8891; Bio-Rad). RT-qPCR assays
for A3B and CCNE2 were performed using the C1000 Thermal Cycler (Bio-Rad). For pretreatment with
PMA (tlrl-pma; InvivoGen; 1-mg/ml stock in DMSO), cells were treated with 0 ng/ml (DMSO) or 25 ng/ml
PMA for 3 h, followed by treatment with 0 M, 0.5 M, and 2.5 M palbociclib. RNA was isolated 0, 1, and
3 h after addition of palbociclib and processed as described above. For pretreatment with palbociclib,
cells were treated with 0 M, 0.5 M, and 2.5 M palbociclib for 30 min, followed by treatment with
0 ng/ml (DMSO) or 25 ng/ml PMA. RNA was isolated 0, 1, and 3 h after addition of PMA and processed
as described above.
Bioinformatics. TCGA expression data were downloaded from the Broad GDAC Firehose as of
January 2016. Expression correlations against A3B by all other genes in the breast cancer cohort were
calculated, and signiﬁcant correlates were used to determine signiﬁcant activation or inhibition of
upstream regulators using Ingenuity Pathway Analysis (Qiagen). All other Spearman correlations and P
values were calculated, and heat maps were plotted using the R statistical environment. P values were
adjusted for multiple comparisons using the Bonferroni correction, and resulting q values were reported.
Cell cycle data were acquired from http://www.targetgenereg.org/ in May 2018.
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